Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Stephen W Webster is Director at Nextcure. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 22, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
NextcureNXTC
Jun 18, 20262,340disclosed Jun 22
DetailsOfficial recordStephen W Webster bought shares on the open market in 2018, and has not bought since 2018.
Stephen W Webster reported 1 open-market purchase and 0 sales since 2018; purchases in 2018.
| Year | Bought | Sold |
|---|---|---|
| 2018 | $42K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Stephen W Webster bought shares on the open market in 2018, and has not bought since 2018.
In SEC filings since 2018: the latest open-market purchase is from 2018; no open-market sale is on record.
Viking Therapeutics (VKTX), from 2018 to 2018: 1 purchase and 0 sales.
Stephen W Webster reported 1 open-market purchase and 0 sales here, 2018.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
